Schema 2 — Hub & Spoke Clinical Workflow

Non-Linear Clinical Decision Module

Tackle clinical domains in any order — just like real practice

This module presents a single patient case with four distinct clinical decision domains. Unlike a linear workflow, you choose which domain to address first. Each domain contains focused questions that test a specific competency. After completing all four, a synthesis question integrates your clinical reasoning across domains. This mirrors how pharmacists actually evaluate complex patients — managing multiple concerns simultaneously and synthesizing findings into a unified plan.

James Rivera, 45M — presents with recurrent UTI symptoms, complex medication history
4 Domains
0.5 CE Credits*
70% Passing

James Rivera, 45M

Chief Complaint
Recurrent dysuria, frequency × 5 days
Key History
HTN (amlodipine), GERD (omeprazole), seasonal allergies
Vitals
BP 128/82, HR 76, Temp 98.4°F, SpO2 99%
Select a Domain
0/2

Diagnosis & Workup

2 Questions
Not Started
0/2

Safety Screening

2 Questions
Not Started
0/2

Drug Interactions

2 Questions
Not Started
Rx
0/2

Dosing & Counseling

2 Questions
Not Started
0 / 4 Domains Complete
Score: 0 pts

Final Integration

Clinical Synthesis

You've evaluated all domains. Now integrate your findings into a final clinical decision.

Assessment Complete

Your Results

Hub & Spoke Clinical Workflow — James Rivera, 45M

0
/ 95 points
0%
--

Synthesis Question

0 / 15

Key Takeaways

  • Always obtain culture before empiric therapy in recurrent UTI — dipstick alone is insufficient for management decisions.
  • Renal function dictates dosing adjustments; eGFR below 50 mL/min requires evaluation of drug clearance pathways.
  • Drug interaction screening must consider CYP enzyme inhibition potential — omeprazole is low-risk, but azole antifungals are high-risk.
  • Comprehensive counseling improves adherence and safety — always address timing, duration, and red-flag symptoms.
  • Clinical synthesis ties all domains together: diagnosis, safety, interactions, and dosing inform one integrated prescribing plan.
Back to Schema Overview